Research explained
Hexarelin vs Ipamorelin: Evidence & Differences
Compare hexarelin and ipamorelin evidence on GH, cortisol and prolactin, separating human hormone studies from animal selectivity findings.
By PurePeptideHub Research Team · Evidence updated
Editorial evidence update; independent clinical review pending. Editorial standards
Hormonal responses in different experiments do not establish a clinical winner, a dose conversion or the safety of long-term use.
Evidence at a glance
Selected sources supporting this update. This is an editorial evidence summary, not a systematic review of every publication.
| Source and design | What it supports | What it cannot establish |
|---|---|---|
| Massoud et al., 1996: hexarelin hormone responses Intravenous dose-response study in healthy adult men | Hexarelin stimulated GH and, depending on exposure, prolactin and cortisol. | An acute endocrine experiment does not establish long-term benefits or safety for other routes. |
| Raun et al., 1998: ipamorelin pharmacology Experiments in cells, rats and pigs | The authors investigated growth hormone release and hormonal selectivity. | Preclinical selectivity does not prove long-term human safety. |
| Beck et al., 2014: postoperative ileus trial Randomized placebo-controlled trial after bowel resection | Key and secondary efficacy analyses found no significant differences from placebo. | This surgical study does not establish benefits for bodybuilding, sleep or general recovery. |
| FDA: ipamorelin safety assessment Regulatory assessment | FDA identifies immune-response concerns and insufficient safety information for some injectable routes. | Missing data are not evidence of safety. |
What do these peptides have in common?
Both are studied as growth hormone secretagogues. A secretagogue stimulates release of a substance; the name does not tell you whether the resulting change improves health. Their evidence should be compared by experimental design and endpoint, not by treating the largest hormone rise as the best result.
Cortisol and prolactin: why the study context matters
The hexarelin experiment measured acute responses in men, while the early ipamorelin selectivity work included animal experiments. Those are not matching treatment groups. They cannot be combined into a numerical ranking of side-effect risk for people.
Is hexarelin stronger than ipamorelin?
Stronger is incomplete without specifying the endpoint, dose, route and time of measurement. A potency difference in an experimental system does not establish better clinical outcomes. We found no basis in these selected sources for a universal stronger-or-better conclusion.
What does the human ipamorelin trial add?
It shows why a promising mechanism still needs outcome testing. Investigators tested a defined clinical question in a surgical setting. That design is more informative for its own question than testimonials, but cannot answer an unrelated comparison about training or recovery.
What remains unknown?
These sources leave comparative long-term safety, patient-relevant benefits and combination effects unresolved. Product identity is another separate question: the paper describes its study material, not the contents of an unrelated vial. A laboratory report and a clinical trial answer different questions.
Regulatory safety context
FDA discusses serious events reported in an intravenous study, including deaths. A reported event does not by itself prove causation, but it should not be omitted from a safety discussion. See the linked assessment.
Common questions
Does ipamorelin never affect cortisol?
That absolute claim goes beyond the selected evidence. The species, sampling window and experimental conditions must accompany any hormone-selectivity statement.
Does a bigger GH response mean better results?
No. Hormone response is a surrogate measurement. Clinical benefit and adverse effects need their own outcome data.
Can these compounds be compared using the same dose?
A matched number of micrograms does not establish biological equivalence. This page provides no dose conversion or combination protocol.
Continue your research
Educational information only. This page does not recommend a medicine, dose or injection protocol. Report a correction with its source.